RATIONALE-304

NCT03663205 📎

Regimen

Experimental
tislelizumab + pem + platinum
Control
pem + platinum

Population

Chinese 1L non-sq NSCLC

Key finding

mPFS 9.7 vs 7.6 mo, HR 0.645 (0.462-0.902); tislelizumab 1L non-sq

Source: PMID 34033975

Timeline

  • Enrollment start: 2018-07-23 📎

Guideline citations

  • CSCO NSCLC 2025 ⚠️ OCR source